Immuneering Announces Participation in November Investor Conferences
November 03, 2022 at 06:50 AM EDT
CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced that management will participate in three November investor conferences to share commentary around the Company’s pipeline, platform, and business strategy. Presenting will be Ben Zeskind, Ph.D., Co-Founder, and Chief Executive Officer and Brett Hall, Ph.D., Chief Scientific Officer.
Immuneering will participate in the following conferences:
Jefferies London Healthcare Conference, London, England
34 Annual Piper Sandler Healthcare Conference, New York, NY
5th Annual Evercore ISI HealthCONx Conference, Virtual
The audio portions of the presentations will be webcast live and archived for 30 days in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.
About Immuneering Corporation